Nektar soared today on cancer drug data–but remember that new opioid? That’s why I say hold even after this run
November 13, 2017 | Daily JAM, NKTR, Stock Alerts | 0 comments
November 13, 2017 | Daily JAM, NKTR, Stock Alerts | 0 comments
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.